Gradientech’s QuickMIC® showed rapid and reliable results in new study

Report this content

Gradientech is pleased to announce positive study results obtained from clinical blood culture samples using QuickMIC, Gradientech’s ultra-rapid antibiotic susceptibility testing (AST) system. The antibiotic susceptibility results were available in an average of 3 hours, which is considerably faster than any other phenotypic AST method in the market.

The study was run in collaboration with Uppsala University Hospital. A total of 41 clinical samples from sepsis patients were analysed using the QuickMIC system. Results for gram-negative bacteria were obtained in an average of 3 hours and had an overall categorical agreement of 94.9% as compared to routine diagnostics. Obtaining fast results is of essence to provide appropriate antibiotic treatment and increase sepsis survival.  
“These results confirm the value of our QuickMIC system for providing reliable results ultra-rapidly” said Sara Thorslund, CEO at Gradientech. “We are very happy with these promising results and looking forward to continue our collaboration with Uppsala University Hospital and other partners around these time-critical samples”.  

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80

About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance.